Key facts
- This page summarizes Bihua Chen's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (HLXB).
- 10 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Aug 2025, 08:28.
Bihua Chen - 11 Aug 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- HLXB
- Reported as of
- 11 Aug 2025
- Net transaction value
- +$74,999,998
- SEC form
- 4
- Accepted by SEC
- 13 Aug 2025, 08:28:26 UTC
- Prior SEC filing
- 01 Aug 2025
- Next SEC filing
- 01 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bihua Chen
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bihua Chen filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (HLXB) on 13 Aug 2025.
Change
- Previous filing in this sequence was filed on 01 Aug 2025.
- Current net transaction value: +$74,999,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001599214
Primary reporting owner
Chen Bihua
- Relationship
- Director, 10%+ Owner
- Address
- C/O HELIX ACQUISITION CORP. II, 200 CLARENDON STREET, 52ND FLOOR, BOSTON
- Signature
- /s/ Bihua Chen
- Signature date
- 13 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBOT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,172,126
- Change %
- +820%
- Price
- Shares after
- 4,681,126
- Date
- 11 Aug 2025
- Ownership
- Via Helix Holdings II LLC
- Footnotes
- F3, F9
BBOT
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $0
- Shares
- -152,940
- Change %
- -3.3%
- Price
- $0.000000
- Shares after
- 4,528,186
- Date
- 11 Aug 2025
- Ownership
- Via Helix Holdings II LLC
- Footnotes
- F4, F9
BBOT
transaction
Common Stock
Award
- Transaction value
- $8,150,464
- Shares
- +760,496
- Change %
- +53%
- Price
- $10.72
- Shares after
- 2,187,536
- Date
- 11 Aug 2025
- Ownership
- Via Fund III
- Footnotes
- F5, F10
BBOT
transaction
Common Stock
Award
- Transaction value
- $6,849,534
- Shares
- +639,110
- Change %
- +71%
- Price
- $10.72
- Shares after
- 1,542,710
- Date
- 11 Aug 2025
- Ownership
- Via Fund V
- Footnotes
- F6, F10
BBOT
transaction
Common Stock
Award
- Transaction value
- $60,000,000
- Shares
- +5,598,425
- Change %
- +8072%
- Price
- $10.72
- Shares after
- 5,667,785
- Date
- 11 Aug 2025
- Ownership
- Via Master Fund
- Footnotes
- F7, F10
BBOT
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,905,046
- Change %
- Price
- Shares after
- 1,905,046
- Date
- 11 Aug 2025
- Ownership
- Via Fund IV
- Footnotes
- F8, F10
BBOT
transaction
Common Stock
Award
- Transaction value
- Shares
- +1,762,760
- Change %
- +114%
- Price
- Shares after
- 3,305,470
- Date
- 11 Aug 2025
- Ownership
- Via Fund V
- Footnotes
- F8, F10
BBOT
transaction
Common Stock
Award
- Transaction value
- Shares
- +284,571
- Change %
- +5%
- Price
- Shares after
- 5,952,356
- Date
- 11 Aug 2025
- Ownership
- Via Master Fund
- Footnotes
- F8, F10
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBOT
transaction
Derivative
Class B ordinary shares
Disposed to Issuer
- Transaction value
- $0
- Shares
- -307,874
- Change %
- -6.9%
- Price
- $0.000000
- Shares after
- 4,172,126
- Date
- 11 Aug 2025
- Ownership
- See footnote
- Underlying class
- Class A ordinary shares
- Underlying amount
- 307,874
- Exercise price
- Footnotes
- F1, F2, F9
BBOT
transaction
Derivative
Class B ordinary shares
Options Exercise
- Transaction value
- Shares
- -4,172,126
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Aug 2025
- Ownership
- See footnote
- Underlying class
- Class A ordinary shares
- Underlying amount
- 4,172,126
- Exercise price
- Footnotes
- F2, F3, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
In connection with and prior to the closing of the business combination (the "Business Combination") between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc. ("Legacy BBOT"), Helix Holdings II LLC (the "Sponsor") forfeited 307,874 Helix Class B ordinary shares for no consideration pursuant to the terms of the Sponsor Support Agreement dated February 28, 2025, between Sponsor, Helix, and Legacy BBOT (the "Sponsor Support Agreement").
Footnote F2
The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading "Description of Securities" in Helix's registration statement on Form S-1 (File No. 333-276591).
Footnote F3
In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis.
Footnote F4
In connection with and immediately prior to the closing of the Business Combination, the Sponsor forfeited 152,940 shares of Common Stock for no consideration, pursuant to the terms of the Sponsor Support Agreement.
Footnote F5
In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of a subscription agreement dated February 28, 2025 between Helix and Cormorant Asset Management, LP (the "Subscription Agreement"), Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 760,496 shares of Common Stock at a purchase price of $10.7173 per share.
Footnote F6
In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 639,110 shares of Common Stock at a purchase price of $10.7173 per share.
Footnote F7
In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 5,598,425 shares of Common Stock at a purchase price of $10.7173 per share.
Footnote F8
Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the "Business Combination Agreement"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP ("Fund IV"), received as consideration therefor, shares of common stock of the Issuer.
Footnote F9
Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly.
Footnote F10
Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
SEC remarks
Ms. Chen serves on the Board of Directors of the Issuer. Sponsor and the Cormorant Funds may be deemed to be directors by deputization as a result of the service of Ms. Chen.